Hit enter to search or ESC to close
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
AI-POWR™
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
Hepion Tackles NASH in P2 with Cyclophilin Inhibitor [Breaking Biotech]
By
Hepion
October 11, 2020
December 2nd, 2020
Media Placements
,
Videos
No Comments
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
January 05, 2021
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020
Share
Tweet
Share
Pin
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
AI-POWR™
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
